Inhibition Mechanisms of α-Glucosidase in Diabetes Management

α-Glucosidase is a key enzyme in the final step of carbohydrate digestion, cleaving terminal glucose residues from oligosaccharides at the intestinal brush border. Inhibition of this enzyme delays glucose absorption and blunts post-prandial hyperglycaemia, thereby improving glycaemic control in type 2 diabetes. Pharmaceutical inhibitors such as acarbose and miglitol have demonstrated clinical efficacy but are often accompanied by gastrointestinal side effects. Recent advances have focused on the discovery and characterisation of novel inhibitors from natural sources, including flavonoids, phenolic acids and peptides, as well as on rational drug design guided by structural biology. Mechanistic studies reveal that small molecules may exhibit competitive, non-competitive or mixed modes of inhibition, while allosteric modulators provide further opportunities to adjust enzyme kinetics without competing directly at the active site. Structure–activity relationship analyses, molecular docking and crystallographic insights have all contributed to a deeper understanding of binding interactions, informing the development of more potent and selective agents. Beyond small molecules, whole-food approaches exploit bioactive components in cereals, vegetables and tubers to achieve dietary modulation of enzyme activity. Together, these strategies underscore a multifaceted approach to diabetes management with both pharmacological and nutritional interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Inhibition Mechanisms of α-Glucosidase in Diabetes Management publication trend

The graph below shows the total number of articles in inhibition mechanisms of α-glucosidase in diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

α-Glucosidase: Enzyme located in the intestinal brush border that cleaves terminal glucose residues from oligosaccharides during digestion.

IC50: Concentration of an inhibitor required to reduce enzyme activity by 50%, a standard measure of potency.

Post-prandial hyperglycaemia: Acute elevation of blood glucose following a meal, a principal target for glucose-lowering interventions.

Competitive inhibition: Mode of enzyme inhibition in which an inhibitor binds to the active site, preventing substrate access.

Non-competitive inhibition: Mode of enzyme inhibition in which an inhibitor binds to a distinct site, altering enzyme conformation and reducing activity irrespective of substrate concentration.

References

1. α-Glucosidase inhibition by flavonoids: an in vitro and in silico structure–activity relationship study. Journal of Enzyme Inhibition and Medicinal Chemistry (2017).
2. Inhibitors of α‐amylase and α‐glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. Food Science & Nutrition (2020).
3. Inhibition of α-glucosidase, α-amylase, and aldose reductase by potato polyphenolic compounds. PLOS ONE (2018).